EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T

Rafael Fonseca, Surbhi Sidana, Kevin C De Braganca, Tamar Lengil, Ahmed Mohamed, Helen Pai, Matthew Perciavalle, Bruno Emond, Todd Bixby, Zaina P Qureshi, Peter Voorhees

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2026.01.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Rafael Fonseca und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Second Primary, Receptors, Chimeric Antigen, Multiple Myeloma. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Scientific Affairs, Legend Biotech USA Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chimeric antigen receptor-T (CAR-T) cell therapies are highly effective in treating hematologic malignancies. Cases of second primary malignancies (SPMs) have been reported post-treatment, although risk factors remain unclear. This real-world study evaluated predictors of SPMs among patients treated with CAR-T. METHODS: Patients with multiple myeloma (MM) or lymphoma/leukemia treated with CAR-T were identified from the Komodo Research Database (January 1, 2016-June 30, 2024). Incidences of SPMs and hematologic SPMs were evaluated following CAR-T infusion (index date) and predictors were evaluated 12 months pre-index. LASSO regression was used to identify predictors of SPMs and hematologic SPMs, separately. Multivariate Cox regression was used to assess the magnitude and direction of each predictor. RESULTS: Among 2,609 patients receiving CAR-T (MM: 683, lymphoma/leukemia: 1,926) and over a median follow-up of 14.5 months, the incidences of SPMs and hematologic SPMs were 11.8% and 5.0%, respectively (0.3% for peripheral T-cell lymphoma). Median time-to-event was approximately 8 months for SPMs and hematologic SPMs. Adjusting for other predictors in the models, there was no association between CAR-T indicated for MM versus lymphoma/leukemia and the risk of SPMs (hazard ratio: 0.85, P = .32). Relative to lymphoma/leukemia, MM was associated with a significantly lower risk of hematologic SPMs (hazard ratio: 0.24, P < .05). CONCLUSIONS: This study found no association between CAR-Ts used in MM versus lymphoma/leukemia and the risk of subsequent SPMs, while a lower risk of hematologic SPMs was observed in patients with MM. T-cell malignancies were infrequent. Ongoing research into potential risk factors of SPMs following CAR-T could help inform individualized management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeoplasms, Second PrimaryReceptors, Chimeric AntigenMultiple MyelomaHumansMaleFemaleMiddle AgedAgedAdultRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

Adverse eventsCAR-T cell therapyLeukemiaLymphomaMultiple myeloma

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ.
  • Stanford Medicine, Stanford, CA.
  • Janssen Research & Development, Raritan, NJ.
  • Legend Biotech USA, Inc., Somerset, NJ.
  • Analysis Group, Inc., Montreal, QC, Canada. Electronic address: bruno.emond@analysisgroup.com.
  • Janssen Scientific Affairs, LLC, Horsham, PA.

Förderung

  • Janssen Scientific Affairs
  • Legend Biotech USA Inc

Zitieren

APA

Fonseca, R., Sidana, S., De Braganca, K. C., Lengil, T., Mohamed, A., Pai, H., Perciavalle, M., Emond, B., Bixby, T., Qureshi, Z. P., & Voorhees, P. (2026). FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.01.006

Vancouver

Fonseca R, Sidana S, De Braganca KC, Lengil T, Mohamed A, Pai H, et al. FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.01.006

BibTeX
@article{Fonseca2026,
  author = {Fonseca, Rafael and Sidana, Surbhi and De Braganca, Kevin C and Lengil, Tamar and Mohamed, Ahmed and Pai, Helen and Perciavalle, Matthew and Emond, Bruno and Bixby, Todd and Qureshi, Zaina P and Voorhees, Peter},
  title = {FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.01.006}
}
Kostenlos starten →